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Background-—Low serum magnesium has been implicated in cardiovascular mortality, but results are conﬂicting and the pathway
is unclear. We studied the association of serum magnesium with coronary heart disease (CHD) mortality and sudden cardiac death
(SCD) within the prospective population-based Rotterdam Study, with adjudicated end points and long-term follow-up.
Methods and Results-—Nine-thousand eight-hundred and twenty participants (mean age 65.1 years, 56.8% female) were included
with a median follow-up of 8.7 years. We used multivariable Cox proportional hazard models and found that a 0.1 mmol/L increase
in serum magnesium level was associated with a lower risk for CHD mortality (hazard ratio: 0.82, 95% CI 0.70–0.96). Furthermore,
we divided serum magnesium in quartiles, with the second and third quartile combined as reference group (0.81–0.88 mmol/L).
Low serum magnesium (≤0.80 mmol/L) was associated with an increased risk of CHD mortality (N=431, hazard ratio: 1.36, 95% CI
1.09–1.69) and SCD (N=217, hazard ratio: 1.54, 95% CI 1.12–2.11). Low serum magnesium was associated with accelerated
subclinical atherosclerosis (expressed as increased carotid intima-media thickness: +0.013 mm, 95% CI 0.005–0.020) and
increased QT-interval, mainly through an effect on heart rate (RR-interval: 7.1 ms, 95% CI 13.5 to 0.8). Additional
adjustments for carotid intima-media thickness and heart rate did not change the associations with CHD mortality and SCD.
Conclusions-—Low serum magnesium is associated with an increased risk of CHD mortality and SCD. Although low magnesium
was associated with both carotid intima-media thickness and heart rate, this did not explain the relationship between serum
magnesium and CHD mortality or SCD. Future studies should focus on why magnesium associates with CHD mortality and SCD
and whether intervention reduces these risks. ( J Am Heart Assoc. 2016;5:e002707 doi: 10.1161/JAHA.115.002707)
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M agnesium is the second most abundant intracellularcation and it plays a key role in a wide range of cellular
functions.1 Total body magnesium depends on dietary intake
and recent studies showed that the vast majority of elderly do
not consume the average dietary requirement for magne-
sium.2 In addition to a magnesium-insufﬁcient diet, elderly are
also at risk for hypomagnesemia due to comorbidities and
medication that increase urinary excretion of magnesium.1
The prevalence of hypomagnesemia in the general population
is estimated at 2%,3 but it may be as high as 53% in speciﬁc
high-risk groups, such as patients with chronic heart failure.4
Although hypomagnesemia may have acute and chronic
complications, serum magnesium is still measured relatively
infrequently.1
In recent studies, low serum magnesium has been
associated with inﬂammation5 and disturbances in the
regulation of vascular tone and endothelial function.6–9 These
mechanisms are thought to contribute to the development
and progression of atherosclerosis, potentially worsening
coronary heart disease (CHD).10,11 Magnesium is also known
for its role in the electrical stability and energy balance of
cardiomyocytes.12 Hypomagnesemia has been associated
with atrial and ventricular arrhythmias and low serum
magnesium could therefore also be a risk factor for sudden
cardiac death (SCD).2,4,13
Previous studies have addressed the relationship between
serum magnesium and CHD11,14 and the relationship with
From the Departments of Epidemiology (B.C.T.K., M.N.N., M.J.G.L., O.H.F., A.H.,
B.H.S.), Internal Medicine (B.C.T.K., R.Z., B.H.S., E.J.H.), Cardiology (M.J.G.L.,
J.W.D.), and Medical Informatics (M.E.B.), Erasmus MC – University Medical
Center Rotterdam, Rotterdam, The Netherlands; Inspectorate for Health Care,
Utrecht, The Netherlands (B.C.T.K., B.H.S.); Department of Epidemiology,
Harvard T.H. Chan School of Public Health, Boston, MA (M.J.G.L., A.H.).
Correspondence to: Bruno H. Stricker, MMed, PhD, Department of
Epidemiology, Erasmus MC – University Medical Center Rotterdam, P.O.
Box 2040, 3000 CA Rotterdam, The Netherlands. E-mail: b.stricker@eras-
musmc.nl
Received November 20, 2015; accepted December 23, 2015.
ª 2016 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley Blackwell. This is an open access article under the terms of the
Creative Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is
properly cited and is not used for commercial purposes.
DOI: 10.1161/JAHA.115.002707 Journal of the American Heart Association 1
ORIGINAL RESEARCH
 by guest on January 4, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
SCD,15,16 but with conﬂicting results for both outcomes.2 In
addition, these studies had few cases or lacked adjudicated
end points, which could have resulted in misclassiﬁcation. We
therefore aimed to study the association of serum magnesium
levels with both CHD mortality and SCD within the Rotterdam
Study, a prospective population-based cohort study among
middle-aged and elderly persons with adjudicated end points
and long-term follow-up. Low serum magnesium has been
associated with accelerated atherosclerosis.17 We therefore
hypothesized that this could be the potential mechanism
through which serum magnesium increases the risk of CHD
mortality. Since carotid intima media thickness (cIMT) is
considered a proxy for accelerated atherosclerosis, we
explored the association between serum magnesium and
cIMT as a potential mediator for the relationship with CHD
mortality. QT prolongation is a well-established risk factor for
SCD18 and serum magnesium was shown to inﬂuence the QT
interval in a clinical setting.19 We therefore hypothesized that
QT prolongation could be the biological pathway through
which low serum magnesium is associated with SCD.
Methods
Study Design, Setting, and Population
This study was embedded within the Rotterdam Study, a
prospective population-based cohort study, ongoing since
1990 in a suburb of the city of Rotterdam, The Netherlands.
The rationale and design of this study have been described in
detail elsewhere.20 In summary, the original cohort consisted
of 7983 unselected inhabitants of the study area, aged
55 years or over. This cohort was extended in 2000 with
3011 persons who had become 55 years of age or who had
moved into the research area, since the start of the study. In
2006, the cohort was extended again with 3932 persons aged
45 years and older living in the research area who had not yet
been invited. This resulted in a total study population of
14 926 individuals, aged 45 years and older. All eligible
participants provided written informed consent to participate
in the study. Separate consent was asked for follow-up data
collection on clinical outcomes and vital status. The Rotter-
dam Study has been approved by the Medical Ethics
Committee of the Erasmus Medical Center and by the Dutch
Ministry of Health, Welfare and Sport, implementing the “Wet
Bevolkingsonderzoek: ERGO (Population Screening Act: Rot-
terdam Study).”
Assessment of Serum Magnesium
For our study, we used blood collections from the third visit of
the ﬁrst cohort (1997–1999), and the ﬁrst visits of the second
cohort (2000–2001) and third cohort (2006–2008), as these
visits were virtually identical in design. Of the 11 740 eligible
participants, serum magnesium was available for 9882
participants. Of these 9882 participants, 59 did not provide
consent to collect follow-up information from their treating
physicians and 3 participants were lost to follow-up at the
date of blood collection and therefore did not contribute to
our study. This resulted in a study population of 9820
participants. Magnesium was measured in serum by the
Department of Clinical Chemistry of the Erasmus Medical
Center using a Roche/Hitachi Cobas c501 analyzer. We
plotted multivariate adjusted log relative hazard curves using
restricted cubic splines, to examine the association between
serum magnesium and CHD mortality. We found this asso-
ciation to be linear and therefore used serum magnesium as a
continuous parameter when quantifying the association with
CHD mortality. The association with SCD was also modeled
using restricted cubic splines and found to be U-shaped.
Therefore, we also divided serum magnesium into quartiles
and analyzed serum magnesium as a categorical variable in all
our analyses. We combined the second and third quartile into
a reference group to best ﬁt the observed U-shape, yielding a
low, high, and reference group.21
Assessment of Covariables
The assessment of anthropometrics in the Rotterdam Study
has been described previously.20 Body mass index was
calculated by dividing body weight in kilograms by height in
meters squared. Diabetes mellitus was deﬁned as the use of
glucose-lowering drugs, a fasting glucose level ≥7.0 mmol/L,
or a nonfasting glucose level ≥11.1 mmol/L when fasting
levels were not available.22 The estimated glomerular ﬁltration
rate (eGFR) was calculated using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation23 and was
expressed as mL/min per 1.73 m2 based on serum creatinine
values that were measured at the same visit as the serum
magnesium levels using an enzymatic assay method. Total
cholesterol and high-density lipoprotein cholesterol were
measured at the same visit as the serum magnesium levels
using the Roche Modular P800. Information on history of
stroke, myocardial infarction, and heart failure was obtained
through linkage with medical records kept by general
practitioners working in the study area, and subsequently
adjudicated by 2 research physicians and conﬁrmed by a
neurologist or cardiologist.24 Information on smoking habits
and current alcohol consumption was obtained during a home
interview. Smoking was categorized into 3 categories: non-
smoker, former smoker, and current smoker. Alcohol con-
sumption was categorized into yes or no. Drug exposure has
been monitored continuously since January 1, 1991 through
linkage with digital pharmacy records of the pharmacies in the
study district. The following Anatomical Therapeutic Chemical
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(ATC) codes were used to retrieve relevant drug exposure for
all participants: verapamil (C08DA01), diltiazem (C08DB01),
b-blocking agents (C07), digoxin (C01AA05), class I/III
antiarrhythmic drugs (C01B), and diuretics (C03).25 The use
of deﬁnite QTc-prolonging drugs was determined using the
University of Arizona list of QTc-prolonging drugs.26 Partici-
pants were classiﬁed as being exposed if the date of the blood
draw fell within the prescription period. Physical activity was
assessed using a validated adapted version of the Zutphen
Physical Activity Questionnaire, and expressed in metabolic
equivalent of task hours per week.27
Assessment of Outcomes
Follow-up time was calculated from the date that blood was
drawn until the date of death, loss to follow-up (n=594), or the
end of the study period (January 1, 2012 for CHD mortality
and January 1, 2011 for SCD). Methods for outcome data
collection and deﬁnitions have previously been described in
more detail.24,28 In short, CHD mortality was deﬁned as
deﬁnite fatal myocardial infarction, deﬁnite fatal CHD, and
possible fatal CHD. Information on the vital status of all
participants was obtained on a weekly basis from the central
registry of the municipality in Rotterdam and through digital
linkage with records from general practitioners working in the
study area. The cause of death was established by abstracting
information from the medical records of the general practi-
tioners or nursing home physicians and hospital discharge
letters. SCD was deﬁned as “natural death due to cardiac
causes, heralded by abrupt loss of consciousness within
1 hour from onset of acute symptoms; preexisting heart
disease may have been known to be present, but the time and
mode of death are unexpected,” according to Myerburgs’
deﬁnition endorsed by the European Society of Cardiol-
ogy29,30 Unwitnessed deaths were coded as SCD if death was
unexpected in persons found dead, while they were in a stable
medical condition 24 hours before they were found in the
absence of evidence of a noncardiac cause.28 Each outcome
was adjudicated by 2 research physicians who independently
classiﬁed information on occurrence, certainty, and date using
standardized criteria and subsequently validated by an
experienced cardiologist.24,28 The classiﬁcation of CHD
mortality (as a cause of death) and SCD (as a mode of death)
overlap and results on CHD mortality could be driven by the
effect on SCD (Figure 1). Therefore, we also deﬁned a
“nonsudden CHD mortality” category including participants
who were only classiﬁed as death from CHD but not as SCD.
c-IMT and ECG Measurements
cIMT correlates with future cardiovascular events and can
therefore be used as a subclinical marker of atherosclerosis.31
We used longitudinal 2-dimensional ultrasound images of the
common carotid artery for a 1-cm length that was proximal to
the bulb, obtained with a 7.5 MHz linear array transducer and
UltraMark IV (Advanced Technology Laboratories, Bethel, WA),
to measure the distance between the lumen intima interface
and the media–adventitia interface, which indicates the cIMT.
The maximal cIMT, summarized as the mean of the maximal
measurements from the near and far walls on both the left and
right sides, was used for analysis.32 Each participant also had a
standard 12-lead resting ECG recorded with an ACTA electro-
cardiograph (ESAOTE, Florence, Italy) at a sampling frequency
of 500 Hz, which was stored digitally. All ECGs were
processed by the standardized Modular ECG Analysis System
(MEANS) to obtain ECG measurements.33 The QT interval
represents the interval between the start of ventricular
depolarization to the end of ventricular repolarization. MEANS
determines this interval from the start of the QRS complex
until the end of the T-wave. Heart rate modiﬁes this interval;
therefore QT-interval measurements are corrected for the
individual’s RR interval to allow comparison by using Bazett’s
correction.34 For all participants, cIMT measurements and ECG
measurement were performed during the same visit, during
which blood was drawn for serum magnesium measurements.
Cardiovascular 
disease mortality 
 
Coronary Heart 
Disease mortality 
Sudden Cardiac 
Death 
N=17 
N=13 
N=187 
N=244 
N=519 
Figure 1. Overlap between the classiﬁcation of coronary heart
disease mortality (as a cause of death) and sudden cardiac death
(as a mode of death). Among all 2303 participants who died during
follow-up, 780 died due to cardiovascular disease, of which 431
participants were classiﬁed as coronary heart disease mortality. Of
these 431 participants, 187 were also classiﬁed as sudden cardiac
death. Seventeen participants were classiﬁed as sudden cardiac
death and cardiovascular deaths (but not coronary heart disease)
and 13 participants were classiﬁed as sudden cardiac death but
could otherwise not be classiﬁed as cardiovascular deaths.
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Statistical Analyses
We used the cmprsk package in “R” to plot cumulative
probability curves for CHD mortality, nonsudden CHD mor-
tality, and SCD adjusted for competing risk of death by other
causes as proposed by Fine and Grey.35 We used Cox
proportional hazard regression models to examine the
relationship between serum magnesium and CHD mortality,
nonsudden CHD mortality, and SCD. We analyzed these
associations using 2 different models. In the ﬁrst model we
adjusted for age (as a continuous variable) and sex. The
second model also included the following continuous vari-
ables: eGFR, body mass index, systolic and diastolic blood
pressure, total cholesterol/high-density lipoprotein choles-
terol ratio, and the following categorical variables: diabetes
mellitus, history of myocardial infarction, stroke, or heart
failure, smoking status, alcohol consumption, and use of
diuretics. We studied the association between serum magne-
sium and QTc interval in a multivariable linear model using the
same covariables and additionally adjusted for drugs that are
known to affect the QT and/or RR interval (see above).
Because Bazett’s formula is known to overestimate at short
RR intervals and underestimate at long RR intervals, we also
additionally adjusted for RR interval.36 The association
between serum magnesium and heart rate (expressed as RR
interval) was also studied using the same covariables. We
tested for potential pathways by additionally adjusting the
second model for QT and RR interval to account for a potential
arrhythmogenic pathway and by including cIMT as marker for
subclinical atherosclerosis. The proportional hazard assump-
tion was tested by plotting log-minus-log survival versus log of
survival time curves and visually examining the curves, which
did not indicate that the assumption was violated.37 Results
are presented as hazard ratios (HRs) with 95% CIs. Missing
data in covariables (0–9.1%) were handled by single imputa-
tion using an expectation-maximization algorithm.38 All anal-
yses were repeated on complete cases to check for potential
differences between results based on imputed data and those
based on complete cases. With the exception of the baseline
characteristics, results are reported for imputed data. We
considered a 2-sided P<0.05 as statistically signiﬁcant. Data
were analyzed using SPSS Statistics (IBM, version 21.0) and R
(The R Foundation for Statistical Computing, version 3.1.2).
Sensitivity Analyses
To further distinguish between an effect of serum magnesium
on accelerated atherosclerosis or serum magnesium having
an anti-arrhythmogenic effect, we studied the association
between serum magnesium and incident myocardial infarction
(MI). If the effect of serum magnesium on CHD mortality is
mediated through accelerated atherosclerosis, an effect on
incident MI would also be expected. We studied the associ-
ation with incident MI only with serum magnesium as a
continuous parameter, as there were only a limited number of
MI events and we expected the shape of the association to be
similar to CHD mortality.
In a previous study, hypertension and cholesterol levels
were found to be intermediates in the association between
plasma magnesium and fatal CHD.39 To explore the effect of
these factors on our effect estimates, we excluded systolic
blood pressure, diastolic blood pressure, and total/high-
density lipoprotein cholesterol ratio from our second model.
We then compared effect estimates of the full model to the
model without blood pressure and cholesterol to check
whether our results had been altered by inclusion of this
potential mediator.
To test the robustness of our ﬁndings, we also performed 2
additional analyses where we restricted our analysis to
participants free of diabetes mellitus and with normal kidney
function (deﬁned as eGFR >60 mL/min per 1.73 m2) in order
to explore potential effect modiﬁcation by diabetes mellitus or
chronic kidney disease. Furthermore, we additionally adjusted
for serum sodium, potassium, and calcium levels to test
whether the association of magnesium with any of the
outcomes could be explained by a concomitant electrolyte
disorder.
We expected physical activity to be a potential confounder
of the association between serum magnesium and CHD
mortality. However, data on physical activity were only
available for a subset of 6385 participants. We therefore
performed a sensitivity analysis on this subset to check
whether inclusion of physical activity would have inﬂuenced
our results.
Results
Baseline Characteristics
Baseline characteristics of our study population are shown in
Table 1. Among the 9820 participants, the mean age was
65.1 years, 56.8% were women, and 96% were of European
descent. The mean serum magnesium level was 0.84 mmol/L
(0.06 mmol/L), with a range of 0.34 to 1.74 mmol/L.
Participants in the low magnesium group (N=2351) more
often used diuretics, and more often had diabetes mellitus.
During a median follow-up of 8.7 years (80 750 person-years
in total), 2303 of the 9820 participants died (23.5%). In 2213
of the 2303 participants who died, a cause of death could be
adjudicated. Among these participants, 780 died of cardio-
vascular disease, of which 431 were classiﬁed as death from
CHD. Of the 2303 participants who died, 217 were classiﬁed
as SCD. Figure 1 shows how the classiﬁcations CHD mortality
and SCD relate.
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Magnesium and Mortality
Figure 2 shows the cumulative probability curves for CHD
mortality, nonsudden CHD mortality, and SCD between the
different groups of serum magnesium, taking competing risk
into account. Table 2 shows the associations between the 3
magnesium groups and mortality. Low serum magnesium was
associated with an increased risk for CHD mortality (HR 1.36,
95% CI 1.09–1.69) and an increased risk for SCD (HR 1.54,
95% CI 1.12–2.11). A marginally insigniﬁcant association was
found with high serum magnesium levels and SCD (HR 1.35,
95% CI 0.96–1.89). Excluding SCD cases from the CHD
outcome resulted in an inverse linear association with serum
magnesium levels. The risk in participants with low serum
magnesium was attenuated (HR 1.27, 95% CI 0.95–1.70) and
an association with lower risk was observed in participants
with high serum magnesium levels (HR 0.69, 95% CI 0.48–
0.98). We tested for a linear association with CHD mortality
and nonsudden CHD mortality and found that a 0.1 mmol/L
increase in serum magnesium was associated with a
decreased risk of CHD mortality (HR 0.82, 95% CI 0.70–
0.96), and nonsudden CHD mortality (HR 0.72, 95% CI 0.58–
0.88). We found no evidence of effect modiﬁcation by sex
(P for interaction=0.436), and therefore did not stratify by sex.
IMT, QT-Interval, and Heart Rate
Table 3 shows the associations between the different mag-
nesium groups and markers of potential pathways that may
play a role in the association between serum magnesium and
CHD mortality and SCD. Low serum magnesium was associ-
ated with a signiﬁcantly higher cIMT (+0.013 mm, 95% CI
0.005–0.020); no association was found in participants with
high serum magnesium. Both low serum magnesium and high
serum magnesium were associated with a signiﬁcantly longer
QTc interval (+1.8 ms 95% CI 0.7–2.9 and +2.2 ms 95% CI
1.1–3.3, respectively). When we additionally adjusted this
analysis on QTc interval for heart rate, we found that the
association remained signiﬁcant, but the effect sizes became
smaller. Therefore, we analyzed the effect of serum magne-
sium on heart rate by studying the association between serum
magnesium and RR interval. We found that both low serum
magnesium and high serum magnesium were signiﬁcantly
associated with RR interval (7.1 ms, 95% CI 13.5 to 0.7
Table 1. Characteristics of the Study Population
Total
n=9820
Low
n=2351
Reference
n=5170
High
n=2299
Age, y 65.1 (9.9) 65.1 (10.2) 64.9 (9.7) 65.6 (10.0)
Women, n (%) 5575 (56.8) 1368 (58.2) 2908 (56.2) 1299 (56.5)
Body mass index, kg/m2 27.3 (4.2) 27.8 (4.6) 27.2 (4.1) 26.8 (4.0)
Systolic blood pressure, mm Hg 140 (21) 141 (21) 139 (21) 140 (22)
Diastolic blood pressure, mm Hg 79 (12) 79 (12) 79 (11) 79 (12)
Smoking, n (%)
Never 2991 (30.8) 661 (28.4) 1600 (31.3) 730 (32.2)
Former 4549 (46.8) 1094 (47.0) 2406 (47.0) 1049 (46.3)
Current 2175 (22.4) 574 (24.6) 1112 (21.7) 489 (21.6)
Alcohol use, n (%) 8274 (85.2) 1919 (82.5) 4430 (86.6) 1925 (84.9)
History of diabetes mellitus, n (%) 1021 (10.4) 466 (19.9) 433 (8.4) 122 (5.3)
History of myocardial infarction, n (%) 494 (5.0) 134 (5.7) 237 (4.6) 123 (5.4)
History of stroke, n (%) 340 (3.5) 92 (3.9) 160 (3.1) 88 (3.8)
History of heart failure, n (%) 257 (2.6) 69 (2.9) 118 (2.3) 70 (3.1)
eGFR, mL/min per 1.73 m2 81.5 (17.3) 83.2 (20.0) 81.8 (16.0) 79.0 (17.0)
Serum magnesium, mmol/L 0.84 (0.06) 0.77 (0.04) 0.85 (0.02) 0.92 (0.04)
Total cholesterol, mmol/L 5.7 (1.0) 5.6 (1.0) 5.7 (1.0) 5.8 (1.1)
HDL cholesterol, mmol/L 1.40 (0.41) 1.38 (0.42) 1.41 (0.40) 1.40 (0.41)
Diuretic use, n (%) 1017 (10.7) 325 (14.2) 418 (8.1) 233 (10.6)
Data are shown for nonimputed data, values are counts (valid percentages) or means (SD). Low magnesium group 0.34 to 0.80 mmol/L, reference group 0.81 to 0.88 mmol/L, high
magnesium group 0.89 to 1.74 mmol/L. eGFR indicates estimated glomerular ﬁltration rate; HDL, high-density lipoprotein.
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and 7.8 ms, 95% CI 14.1 to 1.4, respectively). Due to the
signiﬁcant associations between serum magnesium and cIMT,
QT interval, and heart rate, we hypothesized that cIMT could
be a potential mediator for the association with CHD mortality
and nonsudden CHD mortality, and QT interval or heart rate
could be a mediator in the association with SCD. Table 4
shows the result of additionally adjusting for these potential
mediators. We found that additional adjustment for cIMT did
not change the association between low serummagnesium and
CHD mortality (before adjustment HR 1.36, 95% CI 1.09–1.69;
after adjustment HR 1.35, 95% CI1.08–1.68). The same was
true for the association with nonsudden CHD (before adjust-
ment HR 1.27, 95% CI 0.95–1.70; after adjustment HR 1.26,
95% CI 0.94–1.69). Additional adjustment for QT interval and
heart rate did not change the association between low serum
magnesium and SCD (before adjustment HR 1.54, 95% CI 1.12–
2.11; after adjustment HR 1.50, 95% CI 1.09–2.06).
Sensitivity Analyses
When studying the association between serummagnesium and
incident MI, we found that in our age- and sex-adjusted model a
0.1 mmol/L increase in serum magnesium level was associ-
ated with a decreased risk of MI (HR 0.84, 95% CI 0.72–0.99).
However, this association was no longer statistically signiﬁcant
after further adjustment for potential confounders (HR 0.90,
95% CI 0.76–1.06, data not shown). To study whether blood
pressure and cholesterol could be potential intermediates in the
association between serum magnesium and CHD mortality, we
excluded systolic blood pressure, diastolic blood pressure, and
total/high-density lipoprotein cholesterol ratio from our model.
We found that by removing these variables, our analysis was not
appreciably altered. When restricting all analyses to partici-
pants free of diabetes mellitus and chronic kidney disease
(eGFR >60 mL/min), the relationship found with CHDmortality
and SCD was not altered (Table 5). Additional adjustments for
serum sodium, potassium, and calcium to investigate whether
the effect of serum magnesium on mortality is mediated
through other electrolytes did not alter the point estimates. In
the subset of 6385 participants where data on physical activity
was available, the inclusion of physical activity to the full model
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Figure 2. Estimated cumulative probability curves for coro-
nary heart disease mortality, nonsudden coronary heart disease
mortality, and sudden cardiac death. Estimated cumulative
probability curves are shown for coronary heart disease
mortality (A), nonsudden coronary heart disease mortality (B),
and sudden cardiac death (C) between different groups of
serum magnesium levels, taking into account the competing
risk of death by other causes. Low serum magnesium is deﬁned
as 0.34 to 0.80 mmol/L, medium serum magnesium (refer-
ence) as 0.81 to 0.88 mmol/L, and high serum magnesium as
0.89 to 1.74 mmol/L.
DOI: 10.1161/JAHA.115.002707 Journal of the American Heart Association 6
Serum Magnesium and Cardiac Mortality Kieboom et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on January 4, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
did not change the association between serum magnesium and
CHD mortality, nonsudden CHD mortality, and SCD (data not
shown).
Discussion
In this prospective population-based cohort study among
9820 participants with a median follow-up of 8.7 years, we
found that low serum magnesium was associated with an
increased risk of CHD mortality and SCD. When we excluded
SCD from the CHD mortality end point, we found that higher
serum magnesium levels were associated with a lower risk of
nonsudden CHD mortality. Even though serum magnesium
was associated with QTc, heart rate, and cIMT, this did not
explain the relationship between serum magnesium and CHD
mortality or SCD.
We observed a 36% increased risk of CHD mortality in
participants with low serum magnesium. The association
between serum magnesium and CHD mortality has been
studied previously in a cohort of Finnish men but no
signiﬁcant association was found, possibly because of a low
number of cases (n=230).14 The National Health and
Nutrition Examination Survey Epidemiologic Follow-up Study
(NHEFS) did ﬁnd a signiﬁcant association, but only when
comparing the third quartile of serum magnesium to the ﬁrst
quartile.11 The Nurses’ Health Study analyzed the association
between dietary magnesium and CHD mortality.39 A signif-
icant association was identiﬁed when comparing the highest
with the lowest quintile of dietary magnesium intake, but they
were unable to study the association between serum
magnesium and fatal CHD due to a lack of cases.40
A meta-analysis on the association between low serum
magnesium and fatal CHD, which included the 2 studies
discussed above,11,14 found a nonsigniﬁcant trend towards
an increased risk.9 However, this meta-analysis also included
2 studies with SCD as outcome of interest which, judging
from the Forest plot, were mainly responsible for this
observed inverse effect.2
We analyzed SCD independently of CHD and found a
signiﬁcantly elevated risk for SCD in participants with low
serum magnesium levels. Investigators from the Framingham
Heart Study did not observe an association between low
serum magnesium and SCD.16 However, this study included
only 29 cases of SCD (compared to 217 cases in our study),
and may therefore have lacked power. Investigators from the
Atherosclerosis Risk in Communities Study (ARIC) and from
the Nurses’ Health Study also analyzed the association
between serum magnesium and SCD and both reported a
lower risk for SCD when comparing the highest magnesium
quartile with the lowest magnesium quartile.15,40 The differ-
ence in risk in participants with high serum magnesium
between our study and the other 2 studies could be the result
of differences in kidney function. In comparison to baseline
kidney function from the ARIC Study and the Nurses’ Health
Study, participants within the Rotterdam Study had on
average a 10 mL/min per 1.73 m2 lower eGFR at baseline
Table 2. Association Between Magnesium Groups and Different Types of Mortality
Serum Magnesium Groups Number of Events
Crude Incidence Rate
Per 1000 Person-Years
(95% CI)
Model 1
Hazard Ratio (95% CI)*
Model 2
Hazard Ratio (95% CI)†
Coronary heart disease mortality
Low 134 7.1 (6.0–8.4) 1.53 (1.23–1.90) 1.36 (1.09–1.69)
Reference 206 4.8 (4.1–5.5) 1.00 (Reference) 1.00 (Reference)
High 91 4.9 (3.9–6.0) 0.97 (0.76–1.24) 0.94 (0.73–1.21)
Nonsudden coronary heart disease mortality‡
Low 74 3.9 (3.1–4.9) 1.39 (1.04–1.85) 1.27 (0.95–1.70)
Reference 127 2.9 (2.4–3.5) 1.00 (Reference) 1.00 (Reference)
High 43 2.3 (1.7–3.1) 0.73 (0.52–1.04) 0.69 (0.48–0.98)
Sudden cardiac death
Low 70 4.2 (3.2–5.3) 1.76 (1.29–2.40) 1.54 (1.12–2.11)
Reference 92 2.4 (1.9–2.9) 1.00 (Reference) 1.00 (Reference)
High 55 3.3 (2.5–4.3) 1.32 (0.94–1.84) 1.35 (0.96–1.89)
Low magnesium group ≤0.80 mmol/L, reference group 0.81 to 0.88 mmol/L, high magnesium group ≥0.89 mmol/L.
*Adjusted for age and sex.
†Model 1 additionally adjusted for body mass index, systolic blood pressure, diastolic blood pressure, estimated glomerular ﬁltration rate, history of diabetes mellitus, history of myocardial
infarction, history of stroke, history of heart failure, smoking status, alcohol consumption, total/high-density lipoprotein cholesterol ratio, and diuretic use.
‡This category includes participants who died of coronary heart disease, but who were not classiﬁed as sudden cardiac deaths.
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than the participants from the ARIC Study and Nurses’ Health
Study. The signiﬁcantly elevated risk of SCD in the high serum
magnesium category could therefore still be the result of
residual confounding by kidney function, assuming that a
single eGFR measurement does not capture all changes
associated with a decreased kidney function. We considered
QT prolongation as a potential pathway through which serum
magnesium may affect SCD risk, since prolongation and
shortening of the QT interval is associated with SCD.18,41
However, adjustments for QT and RR interval did not fully
explain the observed associations. An explanation for this
limited change in effect estimate may be that a single
measurement of QT interval does not fully capture all the
electrophysiological changes caused by low serum magne-
sium. Another possibility could be that the effect of serum
magnesium on QT interval is too small to have impact on the
risk of SCD, as it is currently assumed that a minimal increase
of 5 ms is necessary to increase the risk of torsade de
pointes.42
A substantial overlap between participants classiﬁed as
CHD mortality and SCD exists. CHD mortality is a mixture of
modes of death ranging from ischemia-induced ventricular
arrhythmia to chronic ischemic heart failure. SCD is a
particular mode of death that is predominantly caused by
arrhythmias.30 When we limited our outcome to nonsudden
CHD deaths, we still observed a trend toward increased risk in
the low magnesium group. We also observed a potential
protective effect of high serum magnesium on nonsudden
CHD mortality, which has been observed previously in
NHEFS.11 Although this observation combined with the
signiﬁcant effect on cIMT supports a role for magnesium in
atherosclerosis, it does not appear to be the main pathway
since the association between serum magnesium and
nonsudden CHD death remained after adjustment for cIMT.
This could be due to the small effect size of serum magnesium
on cIMT. In previous studies it was shown that per 0.17 mm
increase in cIMT, the risk for acute MI increased by 17%.44
However, in our study, we only found an increase of
0.013 mm when comparing participants with low serum
magnesium with the reference group. It is therefore unlikely
that this small increase would have a large inﬂuence on our
outcome. Furthermore, no association was found between
serum magnesium and incident MI, which would have been
expected if the main effect of serum magnesium is through
accelerated atherosclerosis. This lack of association with
incident ischemic heart disease has been observed previously
in the National Health and Nutrition Examination Survey
study.11 The discrepancy between an effect on CHD mortality
but not on incident MI argues against a direct role of serum
magnesium on accelerated atherosclerosis, making an (acute)
arrhythmogenic effect of serum magnesium more plausible.
Our study has several strengths. First, we did not use total
cardiovascular mortality but studied CHD mortality, nonsud-
den CHD mortality, and SCD separately. The classiﬁcation of
cardiovascular mortality is heterogeneic and often also
includes nonatherosclerotic outcomes such as hemorrhagic
stroke. This heterogeneity makes it difﬁcult to study associ-
ations, since there is also heterogeneity in the underlying
pathophysiology of the various types of cardiovascular
disease. Another strength of our study is the high case load,
and, more importantly, the availability of adjudicated end
points that were blinded from the laboratory results, reducing
potential bias due to differential misclassiﬁcation.
The main limitation of our study was the fact that we only
have a single serum magnesium measurement at baseline and
no follow-up serum magnesium measurements. We therefore
cannot adjust for intraindividual variability over time. How-
ever, a recent study showed that there is a strong correlation
between serum magnesium concentrations measured 1 year
apart,5 suggesting the possibility of an individual setpoint for
serum magnesium, similar to what has been shown for serum
Table 3. Association Between Different Magnesium Groups
and Markers of Potential Pathways
Serum
Magnesium Groups
Model 1
Mean Difference
(95% CI)*
Model 2
Mean Difference
(95% CI)†
Carotid intima-media thickness (in millimeters)
Low 0.023 (0.015–0.030) 0.013 (0.005–0.020)
Reference Reference Reference
High 0.005
(0.013 to 0.003)
0.003
(0.010 to 0.004)
QTc interval (in milliseconds)‡
Low 2.7 (1.6–3.9) 1.8 (0.7–2.9)
Reference Reference Reference
High 2.0 (0.9–3.1) 2.2 (1.1–3.3)
QTc interval (in milliseconds), additionally adjusted for RR interval‡
Low 2.0 (1.0–3.0) 1.3 (0.3–2.3)
Reference Reference Reference
High 1.5 (0.5–2.5) 1.6 (0.6–2.6)
RR interval (in milliseconds)‡
Low 10.1 (16.7 to 3.5) 7.1 (13.5 to 0.8)
Reference Reference Reference
High 7.1 (13.8 to 0.4) 7.8 (14.1 to 1.4)
Low magnesium group ≤0.80 mmol/L, reference group 0.81 to 0.88 mmol/L, high
magnesium group ≥0.89 mmol/L.
*Adjusted for age and sex.
†Model 1 additionally adjusted for body mass index, systolic blood pressure, diastolic
blood pressure, estimated glomerular ﬁltration rate, history of diabetes mellitus, history
of myocardial infarction, history of stroke, history of heart failure, smoking status,
alcohol consumption, total/high-density lipoprotein cholesterol ratio, and diuretic use.
‡In the analysis on ECG parameters, model 2 also includes adjustment for verapamil use,
diltiazem use, b-blocker use, digoxin use, anti-arrhythmic drug use, and QT-prolonging
drug use.
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sodium.44,45 In observational studies, reversed causality
remains a limitation. However, the long-term follow-up after
the serum magnesium measurement decreases the probabil-
ity of reversed causality in our study. Another limitation of our
study is the potential heterogeneity of SCD cases, which is
inherent to the deﬁnition of SCD.46 Generalization to other
ethnic groups is also a limitation, since the participants in the
Rotterdam Study are predominantly of European descent
(96%). Finally, residual confounding can always play a role in
observational studies. We tried to address this by adjusting
for a large number of potential confounders and performing
various sensitivity analyses, which did not indicate substantial
amounts of confounding. A potential confounder for which we
were unable to adjust is diet. Higher dietary magnesium
intake could be a proxy for a healthy diet, therefore resulting
in a lower risk of CHD mortality. We were unable to adjust for
Table 4. Inﬂuence of Potential Pathway Markers on the Association Between Magnesium Groups and Cardiovascular Outcomes
Serum Magnesium Groups
Model 2
Hazard Ratio (95% CI)*
Model 3
Hazard Ratio (95% CI) †
Model 4
Hazard Ratio (95% CI)‡
Coronary heart disease mortality
Low 1.36 (1.09–1.69) 1.34 (1.08–1.68) 1.35 (1.08–1.68)
Reference 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
High 0.94 (0.73–1.21) 0.94 (0.73–1.20) 0.95 (0.74–1.22)
Nonsudden coronary heart disease mortality
Low 1.27 (0.95–1.70) 1.27 (0.95–1.71) 1.26 (0.94–1.69)
Reference 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
High 0.69 (0.48–0.98) 0.69 (0.48–0.97) 0.70 (0.49–0.99)
Sudden cardiac death
Low 1.54 (1.12–2.11) 1.50 (1.09–2.06) 1.53 (1.11–2.10)
Reference 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
High 1.35 (0.96–1.89) 1.32 (0.94–1.85) 1.35 (0.96–1.89)
*Equal to model 2 from Table 2; adjusted for age, sex, body mass index, systolic blood pressure, diastolic blood pressure, estimated glomerular ﬁltration rate, history of diabetes mellitus,
history of myocardial infarction, history of stroke, history of heart failure, smoking status, alcohol consumption, total/high-density lipoprotein cholesterol ratio, and diuretic use.
†Model 2+adjustment for QT interval and RR interval.
‡Model 2+adjustment for carotid intima-media thickness.
Table 5. Sensitivity Analysis on Subset of Participants Free of Diabetes Mellitus and With Normal Kidney Function and Analysis on
the Inﬂuence of Other Electrolytes
Serum Magnesium
Groups
Model 2
Hazard Ratio (95% CI)*
N=9280
Subset of Participants Free
of Diabetes Mellitus and With
Normal Kidney Function
Hazard Ratio (95% CI)†
N=7843
Including Electrolytes
Hazard Ratio (95% CI)‡
N=9280
Coronary heart disease mortality
Low 1.36 (1.09–1.69) 1.44 (1.06–1.95) 1.33 (1.06–1.66)
Reference 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
High 0.94 (0.73–1.21) 0.93 (0.67–1.29) 0.97 (0.76–1.25)
Sudden cardiac death
Low 1.54 (1.12–2.11) 1.67 (1.11–2.51) 1.56 (1.13–2.14)
Reference 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
High 1.35 (0.96–1.89) 1.19 (0.77–1.85) 1.35 (0.96–1.90)
Low magnesium group ≤0.80 mmol/L, reference group 0.81 to 0.88 mmol/L, high magnesium group ≥0.89 mmol/L.
*Equal to model 2 from Table 2; adjusted for age, sex, body mass index, systolic blood pressure, diastolic blood pressure, estimated glomerular ﬁltration rate (eGFR), history of diabetes
mellitus, history of myocardial infarction, history of stroke, history of heart failure, smoking status, alcohol consumption, total/high-density lipoprotein cholesterol ratio, and diuretic use.
†Model 2 in subset of participants free of diabetes mellitus and with normal kidney function (deﬁned as an eGFR >60 mL/min per 1.73 m2).
‡Model 2 additionally adjusted for serum sodium, serum potassium, and serum calcium in all participants.
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this confounder, as dietary assessment was available for only
2504 participants. Since there is only a weak correlation
between serum magnesium and dietary magnesium (R=0.06),
it is unlikely that confounding by dietary magnesium intake
could explain the observed associations.
In conclusion, low serum magnesium is associated with an
increased risk of CHD mortality and SCD. Although low
magnesium has a signiﬁcant effect on subclinical atheroscle-
rosis and heart rate, this did not explain the observed
associations with CHD mortality or SCD. The results from this
and previous studies may provide a rationale to design
intervention studies to analyze whether magnesium supple-
mentation could prove to be effective in lowering the burden
of CHD mortality and SCD.
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